CRNX Crinetics
- 56.090
- +0.030+0.05%
- 57.580
- +1.490+2.66%
Crinetics News
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Morgan Stanley Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $81
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $82
Crinetics Pharmaceuticals: Advancing Cancer Treatment With Novel NDC Platform – A Buy Recommendation
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
Optimistic Buy Rating for Crinetics Pharmaceuticals on Paltusotine's Potential and Robust Pipeline
Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Analysis
Price Target
No Data
No Data